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Abstract
Nodal and Activin are morphogens of the TGFbeta superfamily of signaling molecules that direct differential cell fate
decisions in a dose- and distance-dependent manner. During early embryonic development the Nodal/Activin pathway is
responsible for the specification of mesoderm, endoderm, node, and mesendoderm. In contradiction to this drive towards
cellular differentiation, the pathway also plays important roles in the maintenance of self-renewal and pluripotency in
embryonic and epiblast stem cells. The molecular basis behind stem cell interpretation of Nodal/Activin signaling gradients
and the undertaking of disparate cell fate decisions remains poorly understood. Here, we show that any perturbation of
endogenous signaling levels in mouse embryonic stem cells leads to their exit from self-renewal towards divergent
differentiation programs. Increasing Nodal signals above basal levels by direct stimulation with Activin promotes
differentiation towards the mesendodermal lineages while repression of signaling with the specific Nodal/Activin receptor
inhibitor SB431542 induces trophectodermal differentiation. To address how quantitative Nodal/Activin signals are
translated qualitatively into distinct cell fates decisions, we performed chromatin immunoprecipitation of phospho-Smad2,
the primary downstream transcriptional factor of the Nodal/Activin pathway, followed by massively parallel sequencing, and
show that phospho-Smad2 binds to and regulates distinct subsets of target genes in a dose-dependent manner. Crucially,
Nodal/Activin signaling directly controls the Oct4 master regulator of pluripotency by graded phospho-Smad2 binding in
the promoter region. Hence stem cells interpret and carry out differential Nodal/Activin signaling instructions via a
corresponding gradient of Smad2 phosphorylation that selectively titrates self-renewal against alternative differentiation
programs by direct regulation of distinct target gene subsets and Oct4 expression.
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Introduction
Morphogens are secreted signaling molecules that orchestrate
the spatial distribution and sequence of cellular differentiation
events throughout embryonic development. The specific cell types,
their localization and order of induction from recipient stem cell
populations are determined by the concentration gradient of
morphogens diffusing from the source of secretion. Previous
studies have proposed some of the models by which morphogen
gradients are initiated, established and stabilized including the
level of receptor occupancy, positive/negative feedback and feed
forward mechanisms [1–3]. However, little is understood about
the transcriptional mechanisms responding to variable receptor
activation and how they permit pluripotent stem cells to interpret
signaling levels and direct the appropriate differentiation programs
during mammalian development.
Nodal and Activin are morphogens of the TGFb superfamily of
signaling molecules. In Xenopus embryos, Activin is a potent
concentration-dependent inducer of mesoderm, mesendoderm
and endoderm in animal cap cells [2,4,5]. Nodal has also been
shown to be a classical morphogen in zebrafish where it functions
in a concentration gradient independently of any relaying
mechanisms [6]. In the early mouse embryo, mutations that
perturb the level of Nodal/Activin signaling show that the
pathway plays crucial roles in the induction of the primitive
streak/mesoderm, mammalian organizer (node), mesendoderm
and endoderm during the establishment of the anterior-posterior
axis [7–11]. In contrast to in vivo evidence that Nodal/Activin
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pathway also paradoxically has important roles in the mainte-
nance of self-renewal and pluripotency. Indeed Activin A is
frequently used directly in culture for the continued propagation
and expansion of human embryonic and mouse epiblast stem cells
[12–15].
The signaling level of the Nodal/Activin pathway is determined
by the overall activity of its components many of which have been
identified. Both the Nodal and Activin ligands bind to the same
type I/II serine-threonine receptor kinase complexes consisting of
ActRIIA/B and Alk4/5/7 respectively in the mouse [16]. Nodal
requires the cofactors Cripto/Criptic for receptor activation as
opposed to Activin that can bind directly to the receptors and is
inhibited by Cripto [17–19]. Upon ligand docking, the Type I
receptors phosphorylate the downstream signal transducers
Smad2 and Smad3 (Smad2/3) which form hetero- or homodimers
and trimers [20]. Both Smad2/3 are also phosphorylated by
crosstalk with EGF/ERK/MAPK signaling [21–23] but only the
serine residues of the SSXS motif on the extreme carboxy
terminus are specifically phosphorylated by Nodal/Activin/
TGFbeta signaling. This phosphorylation is important for the
translocation of Smad2/3 to the nucleus in association with
Smad4 [24,25] where the complex recruits a number of
transcription factors including FoxHI, p53, b-catenin and Jun/
Fos for the direct regulation of target genes [20]. Specificity of the
Smads for their direct target genes is partly conferred by a DNA
domain in the MH1 region to the Smad-binding DNA element
(SBE) consisting of a basic CAGA sequence or its complement
[26]. The other partner transcription factors within the complex
are required for additional target gene affinity and specificity.
While Smad2/3 share more than 90% protein homology, they
are not functionally equivalent. Full-length Smad2 differs from
Smad3 as the presence of an inhibitory domain in the MH1 region
prevents direct DNA binding while Smad3 can bind directly to
SBE boxes [27]. However, an alternatively spliced variant of
Smad2 that lacks the inhibitory domain can bind DNA directly
and has been shown to be the isoform that accounts for all
developmental Smad2 functions in vivo [28]. The developmental
roles of Smad2/3 are also disparate. Smad2 knockout mouse
embryos fail to form mesoderm and endoderm due to defects in
primitive streak specification after implantation at 6.5 dpc [29]
closely phenocopying Nodal mutants [10]. In contrast, Smad3
mutant mice are born alive and are fertile but develop chronic
intestinal inflammation leading to colorectal cancer [30]. This
suggests that Smad2 is the primary transcriptional mediator of
early developmental events while Smad3 is involved in immune
function and possibly acts as a tumor suppressor postnatally.
Our focus here is to clarify how mechanistically different levels
of Nodal/Activin signaling lead to different embryonic stem (ES)
cell fate decisions. ES cells were differentiated using three different
quanta levels of Nodal/Activin signaling. We showed that ES cells
are able to arbitrate between three distinct cell fate decisions.
Maintenance of endogenous Nodal/Activin signaling is required
for self-renewal of ES cells where any perturbation leads to an exit
from self-renewal and pluripotency programs towards mesendo-
derm induction at high signaling and trophectoderm differentia-
tion at low signaling.
One obvious question to resolve is whether different levels of
Nodal/Activin signaling recruit different sets of genes. While
genome wide transcriptome studies have suggested possible
Nodal/Activin targets, the identity of many transcriptional targets
directly regulated by Smad2/3 remains unknown. One ChIP-chip
study to date has been performed to address endogenous Smad2/3
binding in transformed human keratinocytes [31] while none have
been carried out in the context of stem cell fate decisions, graded
Nodal/Activin signaling or examining beyond promoter regions.
Here we performed quantitative chromatin immunoprecipitation
(ChIP) of phospho-Smad2 (pSmad2) during graded Nodal/Activin
signaling followed by massively parallel sequencing (ChIP-Seq)
covering the full extent of pSmad2 binding to the ES cell genome
including 59/39 UTRs, exons/introns and gene deserts. PSmad2
binding and regulation of direct target gene expression does not
vary uniformly across the genome but changes in both a
qualitative and quantitative manner with different signaling levels.
Some targets are up- or downregulated proportionate to the
activity of the Nodal/Activin pathway. However, separate subsets
of target genes are regulated only during high or low signaling
conditions. The downstream consequences of this is differential
expression of the target genes that combine dose-dependent genes
with different subsets of genes activated or repressed specifically for
each signaling level. Thus ES cells carry out alternative cell fate
decisions via the recruitment of target gene subsets in a pSmad2
dose-dependent manner.
To reconcile some of the conflicting functions of Nodal/Activin
signaling in self-renewal and pluripotency versus differentiation
cell fate decisions, we examined the regulation of the Oct4
pluripotency and self-renewal master gene. Oct4 was directly
regulated by pSmad2 binding in the promoter region independent
of all other cis regulatory elements. Consistent with the
modulation of pSmad2 binding, both endogenous mRNA and
protein levels of Oct4 were also repressed by inhibition of Nodal/
Activin signaling. Hence pSmad2 is a direct upstream regulator of
Oct4 transcription where it permits an exit from maintenance of
the stem cell state towards mesendoderm or trophectoderm
differentiation programs as specified by the signaling level.
In conclusion, the molecular switching of binding locations and
target genes by pSmad2 across the ES cell genome in a dose-
dependent manner provides a mechanism for the shift in the
balance between maintenance of the stem cell state and the
opposing induction of differentiation. Key signaling pathways have
Author Summary
Nodal and Activin are extracellular signaling molecules
that diffuse from the source of secretion and induce
recipient stem cells to become new cell types according to
a concentration gradient. In the early embryo, they are
important for the specification of tissues at the correct
place and time, but paradoxically they drive the opposite
function in embryonic and epiblast stem cells where they
maintain the stem cell state instead of promoting
differentiation. The molecular basis of how the level of
signaling determines stem cell fate decisions remains
poorly understood. We found that Smad2, the main
transcription factor of the Nodal/Activin pathway was
phosphorylated according to the level of signaling. By
mapping where phospho-Smad2 binds in the embryonic
stem cell genome and how this affects transcription of the
associated target genes, we show that phospho-Smad2
can recruit and regulate different sets of target gene
depending on the signaling level. Moreover, phospho-
Smad2 also directly regulates Oct4, a master gene
controlling the stem cell state thereby reconciling the
opposing functions of the Nodal/Activin pathway in
differentiation versus self-renewal programs. The pathway
can mediate the exit from self-renewal via Oct4 and
simultaneously drives differentiation towards particular
lineages by recruiting the relevant gene subsets for this
purpose.
Nodal/Activin Signaling in ES Cell Fate Decisions
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either present or absent in a biological system. This view has only
been able to account for some of their many and often conflicting
roles. Our findings challenge this view and support multi-level
signaling in stem cells where different signaling strengths can
engender different cell fate decisions reflective of the in vivo
development of embryos directed not just by Nodal/Activin
signaling but possibly Hedgehog, FGF, Wnt and other morphogen
pathways.
Results
The Peak of Transcriptional Activity Induced by Graded
Nodal/Activin Signaling Occurs at 18 Hours
The direct cellular function of the Nodal/Activin pathway
notably of the downstream components Smad2/3/4 is for the
regulation of transcription. To address the relation between
graded signaling and how they affect transcription, we quantified
the changes in expression of known target genes under different
signaling levels in chemically defined KSR media conditions.
Pluripotent mouse embryonic stem (ES) cells were used to assess
the mechanism of morphogen activity as they can differentiate into
all tissue types of the adult and express all components of the
pathway permitting response to manipulated Nodal/Activin
signaling.
Some of the known target genes include Pitx2 and Lefty2 which
are responsible for the establishment of left-right asymmetry
during early embryogenesis, a key developmental role of Nodal/
Activin signaling [32]. In addition, both Lefty2 and Smad7 function
as inhibitors of the pathway in a negative feedback mechanism for
the attenuation of Nodal/Activin signaling strength [33,34].
Although direct Smad2/3 binding and regulation of the Pitx2
and Lefty2 genes have not yet been demonstrated, in vivo reporter
assays suggest that specific enhancers are responsive to Nodal/
Activin signaling and are active only on the left side of the embryo
[35,36]. Moreover, these enhancers have been shown to contain
FoxH1 binding sites, a known key transcriptional copartner of
Smad2/3. Smad7 has been shown to be a direct target of Smad2/
3/4 binding in the promoter region by gel shift assays [37,38] and
it antagonizes the interaction of Smad2/3 with the Type I kinase
receptors [39] during negative feedback.
Using real-time PCR quantitation, the expression of the 3 target
genes was examined in the ES cells following the induction of high
signaling by direct treatment with Activin in a time-course. In the
reciprocal experiment, the small chemical inihibitor SB-431542
that specifically prevents the kinase domains of the Type I kinase
receptors from phosphorylating Smad2/3 [40] was used to
generate low Nodal/Activin signaling conditions. Pitx2, Lefty2
and Smad7 were up- and downregulated in direct correlation with
the level of signaling under chemically defined conditions
compared to the DMSO carrier control representing endogenous
or medium signaling (Figure 1). Over the course of 24 hours, the
maximum expression of Pitx2 and Lefty2 occurred at 18 hours
(Figure 1A and 1B) while that of Smad7 (Figure 1C) occurred
earlier at 12 hours. We therefore conclude based on these known
target genes that Nodal/Activin signal transduction and its effects
on transcription require up to 18 hours to fully develop and any
earlier time points result in weaker inductions.
We further confirmed that Pitx2, Lefty2 and Smad7 are direct
targets of the Nodal/Activin pathway by conducting chromatin
immunoprecipitation of phosphorylated Smad2 in the ES cells
under the same chemically defined conditions at 18 hours followed
by quantification of the enriched genomic DNA fragments by real-
time PCR using tiling primers (Figure S1 and Table S3). The
antibody used for the pulldown was raised against the phosphor-
ylated serines 465 and 467 on the carboxy-terminus of Smad2 that
are specifically targeted by TGFbeta signaling and not by EGF/
ERK/MAPK signaling. At 18 hours where there is maximum
expression of the 3 target genes, there was also a robust divergence
in the level of pSmad2 binding according to the signaling level for
the enhancers of Pitx2 and Lefty2 (Figure S1A and S1B).
Interestingly pSmad2 binding was invariant on the known
TGFbeta response element of the Smad7 promoter (Figure S1C).
This suggested that Nodal/Activin target genes had different
binding efficiencies for pSmad2 at each Nodal/Activin signaling
level and this was not uniformly changed for all target genes.
In conclusion, we confirm that Pitx2, Lefty2 and Smad7 were
direct targets of Nodal/Activin signaling and graded pSmad2
binding. Differential signaling sustained for 18 hours also leads to
the maximum level of differential gene expression with clear
changes in pSmad2 binding on the Pitx2 and Lefty2 genes.
Graded Nodal/Activin Signaling Mediates 3 Distinct Cell
Fate Decisions in ES Cells
Given the downstream changes in pSmad2 binding and
transcription of the known direct target genes, we next addressed
how extracellular signal levels are translated into intracellular
levels of signal transduction. We hypothesized that this could be
directly related to changes in pSmad2 levels in ES cells as a
consequence of Type I receptor kinase activity. Hence ES cells
subjected to differential morphogen signaling conditions may be
able to produce different amounts of pSmad2 in cells generating a
corresponding differential level of intracellular signaling that leads
to differential transcription.
It has recently been shown that overexpression of the
constitutively active Alk4 type I kinase receptor is sufficient to
drive phosphorylation of Smad2 independent of all other Nodal/
Activin receptor complex components [41]. Here we show that
direct treatments of the ES cells with Activin and the specific Type
I receptor kinase inhibitor SB-431542 in chemically defined
conditions also tightly regulates receptor complex activity and
produces the phosphorylation of Smad2 in a signaling dependent
manner (Figure 2A). During Activin stimulation (high signaling)
for 18 hours, there is a defined 2-fold increase in pSmad2 levels
while repression with 10 mM SB (low signaling) leads to a 2-fold
decrease that is within the limits of physiological change compared
to the DMSO vehicle control (equivalent of medium signaling).
Differential signaling had no effect on the equilibrium of total
Smad2 suggesting that only phosphorylation and not regulation of
the total Smad2 population is mediated by Nodal/Activin
signaling. Hence extracellular signaling levels are translated into
an equivalent gradient of intracellular Smad2 phosphorylation in
ES cells.
Subsequently we addressed the long-term consequences of
increased and decreased signaling on ES cell fate decisions by
examining how manipulation of the pathway recapitulates in vivo
cell fate decisions by direct treatment with Activin or SB for 6
days. Analysis of a broad range of early cell fate markers
(Figure 2B) shows that enhanced Nodal/Activin signaling
promotes mesendoderm differentiation in ES cells with strong
upregulation of mesendodermal lineage genes including Gsc, Mixl,
Eomes and Fgf8. The marker for mesoderm, Brachyury (T), was also
strongly induced although this was not reflected by the other
mesodermal markers such as Flk1 and Tbx6. This was consistent
with the finding that T is also co-expressed in mesendoderm in vivo
at the anterior primitive streak [42]. Taken together, this suggests
that high signaling induced by Activin predominantly drives
mesendoderm differentiation.
Nodal/Activin Signaling in ES Cell Fate Decisions
PLoS Genetics | www.plosgenetics.org 3 June 2011 | Volume 7 | Issue 6 | e1002130Figure 1. Pitx2, Lefty2, and Smad7 Are Transcriptional Targets of Graded Nodal/Activin Signaling. Real-time PCR quantification of
changes in mRNA levels for (A) Pitx2, (B) Lefty2 and (C) Smad7 in mouse ES cells during a 0 to 24 hours time course under graded Nodal/Activin
signaling conditions. High signaling was induced by direct treatment with 25 ng/ml Activin (red), low signaling with 10 uM of SB431542 inhibitor
(green) and a control treatment with 1/5000 dilution of DMSO carrier (blue) was carried out following pretreatment of all cells for 6 hours in
chemically defined KSR media with 10 mMS B( 26 to 0 hours). b-actin was used as a housekeeping control and error bars show s.e.m for n=3
replicates.
doi:10.1371/journal.pgen.1002130.g001
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PLoS Genetics | www.plosgenetics.org 4 June 2011 | Volume 7 | Issue 6 | e1002130Figure 2. Smad2 Phosphorylation and Induction of Distinct Cell Fate Decisions Are Determined by Differential Nodal/Activin
Signaling. (A) Western blot and densitometry quantitation of Smad2 phosphorylation in ES cells after 18 hours stimulation with Activin (ACT) and
inhibition with SB-431542 (SB) compared to DMSO vehicle control at the indicated doses in chemically defined KSR media. The same blot was
stripped and reprobed with total Smad2 and Pcna loading control antibodies. Secondary band in the total Smad2 blot corresponds to cross-reaction
with total Smad3. Graph shows densitometry measurements of pSmad2 protein bands relative to total Smad2 in each treatment with the DMSO
control at 100%. (B) Real-time PCR analysis of early cell fate markers in differentiated ES cells after 6 days treatment in ACT, DMSO and SB normalized
to b-actin housekeeping control. Top panel shows induction of markers in ACT treatments expressed as fold change over the control KSR media.
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the upregulation of trophectoderm specific markers including
Dlx3, Esx and Hand1 and a less significant induction of extra-
embryonic primitive endoderm markers such as Gata4/6 and
Pdgfra. Similar results were obtained when the ES cells were
treated with recombinant Lefty1 protein for the same period of
time (data not shown) suggesting that the trophectoderm induction
was specific to low Nodal/Activin signaling. Interestingly there
was no induction of mesendodermal markers as in the Activin
treatment and instead some of these such as Gsc, Mixl and Fgf8
were strongly downregulated. Together, these results suggest that
perturbation of the level of Nodal/Activin signaling and
consequently endogenous Smad2 phosphorylation led to an exit
from self-renewal in ES cells towards highly divergent cell fate
decisions of either mesendoderm or trophectoderm differentiation.
To confirm these results, fluorescent immunostaining was
carried out to assess the protein markers of trophectodermal and
mesendodermal lineages (Figure S2) after differentiation in serum
containing media. The cell fates obtained under these conditions
are similar to the results from the marker analysis performed in
chemically defined conditions. Differentiated cells staining positive
for Mixl and Lim1 in the nucleus could be detected in Activin
cultures. Similarly, Hand1 and placental Cadherin (P-cad) positive
giant cells could also be derived from SB treated ES cells. Control
treatments with a low dose of DMSO carrier (1/5000 dilution)
contained large populations of ES cells that stained strongly for
Oct4 and SSEA-1. These results confirmed that the level of
Nodal/Activin signaling is responsible for at least 3 cell fate
decisions. The endogenous level of signaling is permissive for self-
renewal and maintenance of pluripotency, an increase in signaling
leads to the induction of mesendoderm like cells while reduction of
signaling results in trophectoderm differentiation.
Differential Levels of Nodal/Activin Signaling Regulates
the Expression of Distinct Subsets of Target Genes
We hypothesized that for divergent differentiation programs to
be initiated in ES cells, differential gene expression mediated by
pSmad2 transcription would be a pre-requisite, which is in turn
dependent on the level of Nodal/Activin signaling. Each discrete
signaling threshold should induce an independent and unique
transcriptional signature distinct from other thresholds. To
determine the genetic targets regulated downstream of Nodal/
Activin signaling and their pattern of expression, microarray
analysis was carried out to examine genome-wide gene expression
following Activin, DMSO or SB treatments in chemically defined
KSR media for 18 hours.
No significant changes in gene expression out of 26,000 probes
could be detected between the DMSO and KSR media control
suggesting that the effect of the low concentration of DMSO was
negligible on ES cells (Figure 3A). In contrast, Activin and SB
treatments induced specific changes in gene expression compared
to the DMSO and KSR media controls. Most significantly, we
were able to identify subsets of target genes that were regulated by
one signaling level and not the other consistent with our hypothesis
of threshold specific target gene regulation. For example, 19 genes
including Gdf15, Msmb and Orai3 were consistently upregulated in
Activin treated cells while showing no significant changes in SB. In
contrast, a larger subset of 131 target genes were specifically up-
and down-regulated only in the SB treatment and not in Activin. A
core subset of 12 targets was co-regulated by both high and low
signaling changing their expression in correlation with the
treatment including the known Nodal/Activin target genes
Lefty1/2 and Pitx2 that were upregulated by Activin and down-
regulated in SB.
Interestingly, the number of SB regulated targets significantly
exceeds that of Activin targets, suggesting that endogenous Nodal/
Activin signaling in ES cells is high or near saturation levels such
that a 2-fold increase in pSmad2 could only induce a smaller
subset of genes compared to a 2-fold downregulation. Higher
doses of Activin treatments and greater than 2-fold increases in
pSmad2 may be required to mirror the strength of SB inhibition
providing an explanation for asymmetric up- or downregulation of
gene expression during different levels of signaling. Some of the
target genes driven by Nodal/Activin signaling were indeed
implicated in the mesoderm, endoderm and trophectoderm
lineages. Fgf15 plays an important role in the development of
cardiac mesoderm [43] and Chst15 is specifically expressed in
definitive endoderm in vivo [44] with both targets being
upregulated by Activin. For SB treatments, Gata3, Tcfap2c and
Igf2 were specifically upregulated. Gata3 is a driver of trophecto-
derm development [45,46] while Tcfap2c is expressed specifically
in the placenta where it regulates essential ADA expression [47,48]
and Igf2 is an imprinted gene that modulates nutrient supply
between the placenta and fetus [49,50]. Together these target
genes support some of the mesendodermal and trophectodermal
differentiation programs that may be initiated at 18 hours after the
induction of differential Nodal/Activin signaling. With longer-
term graded Nodal/Activin signaling over 6 days differentiation, it
is likely that additional target genes reinforcing the specification of
both lineages may be brought into play over time.
Lefty1, Pitx2, Fgf15 and Spsb1 were validated by RT-PCR
(Figure 3B) to be co-regulated target genes of high, medium and
low signaling displaying a gradient of expression following the
signaling level. Cripto, Bcar3, Nphs1 and Cdh3 were targets that were
predominantly downregulated by SB inhibition of signaling
showing no significant change during Activin stimulation.
Conversely, the ID1/2/3 family of transcriptional repressors and
Serping1 are specifically upregulated only by the SB treatment
showing no difference in response to either Activin or the DMSO
control. Hence we conclude that different thresholds of Nodal/
Activin signaling are indeed able to regulate the expression of
specific subsets of target genes providing an important explanation
for the establishment of divergent differentiation programs.
Phospho-Smad2 Binding to Target Gene Subsets and
Regulatory Elements Changes Dynamically Depending
on the Level of Nodal/Activin Signaling
While whole genome microarrays are able to identify the
putative subsets of target genes differentially expressed during
specific Nodal/Activin signaling levels, this does not provide a
molecular mechanism for how different target genes can be
directly regulated by the same pathway at different signaling
strengths. To address this question, we examined the recruitment
of the pSmad2 transcription factor to target genes after subjecting
ES cells to Activin, SB or DMSO control treatments in chemically
defined KSR media that produce 2-fold up- and downregulation
of Smad2 phosphorylation by 18 hours. ChIP-Seq of pSmad2 was
employed to identify where pSmad2 was binding on a whole
genome scale in parallel cultures of ES cells under the 3 signaling
Bottom panel shows fold change in marker expression during SB treatment compared to KSR media supplemented with 1/5000 DMSO vehicle. Error
bars show standard error of the mean (s.e.m) for n=4 replicates.
doi:10.1371/journal.pgen.1002130.g002
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PLoS Genetics | www.plosgenetics.org 6 June 2011 | Volume 7 | Issue 6 | e1002130Figure 3. Increased and Decreased Nodal/Activin Signaling Leads to Transcriptional Regulation of Specific Subsets of Target
Genes. (A) Heatmap showing microarray analysis of ES cells after 18 hours treatment with Activin (ACT), SB or DMSO vehicle control in KSR media.
Transcript levels are expressed as log2 fold change over the average of DMSO controls with red showing upregulation and green showing
downregulation in n=4 biological replicates from passage numbers 20 to 24 (P20-P24). Highlighted gene names indicate known roles or domains of
expression in endoderm (red), mesoderm (blue), trophectoderm (green) or cancer (magenta). Color bar shows fold change in gene expression on a
log2 scale. (B) RT-PCR validation of target genes identified in the microarrays that are specifically regulated in ACT and/or SB treatments compared to
the DMSO control. Ywhaz was used as a housekeeping control.
doi:10.1371/journal.pgen.1002130.g003
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a similar depth of 10-13 million tags. Interestingly the number and
magnitude of pSmad2 binding events did not correspond to the 2-
fold up- or downregulation of pSmad2 in ES cells under Activin
and SB treatments. In fact the greatest number of binding peaks
(7423) occurred in the control DMSO condition that maintains
self-renewal and pluripotency of ES cells (Figure 4A). When
homeostatic Nodal/Activin signaling was perturbed by Activin
and SB treatments, the number of binding events decreased to
5094 and 4859 respectively suggesting that any change in the
levels of endogenous pSmad2 from the ES cell undifferentiated
condition also caused a dynamic change in pSmad2 binding across
the ES cell genome. The lower numbers may also be reflective of
the transition where pSmad2 is dissociating from former target
genes and establishing the recruitment of new genes. This was
further supported by the percentage of overlapping peaks that
were common to the 3 treatments being relatively small at 10.3%
with a significantly larger number of unique peaks appearing in
specific treatments (37.25% in DMSO, 20.44% in SB and 19.5%
in Activin out of 12979 total peaks in the union).
A previous study has profiled Smad2/3 binding sites using
promoter arrays in human keratinocytes [31]. However, reporter
assays on Nodal/Activin responsive target genes such as Lefty1/2,
Nodal [36,51] and Pitx2 [35] suggest that Smad2/3 may also
regulate DNA elements in the introns rather than at the promoter
region. Consistent with the reporter assay studies, our ChIP-Seq
data showed that the majority of pSmad2 binding (Figure 4B)
occurs in introns (,30%) with only a minority of sites in the
proximal promoters (,10%). Furthermore, there was a significant
shift in pSmad2 binding from the distal 59 and 39 regions towards
the promoters of genes in the SB treatment compared to DMSO
and Activin (Figure 4B). Examination of binding specifically in the
promoter region showed a clear preference for pSmad2 to
associate in the +/2600 bp proximal region of transcriptional
start sites (TSS) with a steady decrease in binding further away
from the TSS (Figure 4C). In addition, the increase in number of
pSmad2 binding peaks during low signaling with the SB treatment
can be confirmed in the promoter region both up- and
downstream of the TSS. In conclusion, pSmad2 binding, similar
to the changes in gene expression identified by microarrays, also
demonstrates binding to distinct subsets of genomic locations at
different signaling levels.
Phospho-Smad2 Binding Is Positively Associated with
Transcriptional Activity and Its Binding Preference for
Specific DNA Motifs Changes with Signaling Levels
We next examined the relationship governing the degree of
pSmad2 binding and the level of transcription across the genome
(Figure 5A). In all 3 conditions, a clear trend emerges suggesting
that more pSmad2 binding drives higher levels of gene expression.
However, the possibility that pSmad2 is not driving expression but
preferentially associates with more transcriptionally active genes
and open chromatin cannot be excluded. To distinguish between
the 2 possibilities, we examined the trend between pSmad2
binding events and differential gene expression from the micro-
array analysis in the 3 signaling conditions. Indeed, a significant
majority (64.2%) of microarray target genes had pSmad2 binding
within +/250 kb and all displayed .1.5 fold change in binding in
each signaling condition or had different number of binding events
or changed the location of pSmad2 binding (Table S1) suggesting
that the pattern of gene expression was indeed dynamically driven
by pSmad2-DNA interactions.
To account for how pSmad2 is able to switch binding locations
during differential Nodal/Activin signaling, we examined its
preference for specific DNA motifs under each condition. It is
known that Smad2/3 are able to bind directly the basic CAGA
motif and at the same time they possess a number of partner
transcription factors that modulate the specificity and strength of
binding. Here we see that there is strong pSmad2 association with
the basic CAGA SBE specifically in the Activin treatment
(Figure 5B). This was also confirmed when we examined the
strong CAGAC canonical SBE as defined by the TRANSFAC
PWM database which also appears with high frequency at the
center of pSmad2 ChIP-seq peaks in the Activin treatment and not
in DMSO, SB or the random mouse genome sequence control
(Figure 5C). This suggests that both CAGA and CAGAC
displayed graded pSmad2 binding that varied with the signaling
level and were preferentially bound in the Activin condition. To
compare the contribution of CAGA against non-CAGA sequences
towards pSmad2 binding, the top 10 de novo motifs in each
condition were identified using the Weeder program (Figure 5D).
Motifs that occurred with significant frequency but were not
enriched in the center of pSmad2 ChIP-Seq peaks were excluded
to remove the influence of comotifs around the peaks. A number of
non-CAGA motifs that occurred with similar or greater frequency
than CAGA were isolated. Interestingly, these de novo motifs also
showed a graded effect on pSmad2 association similar to the
CAGA SBE. Other non-CAGA motifs were preferentially bound
by pSmad2 only in the DMSO and SB condition and depleted
during the high signaling Activin condition. This suggested that
while CAGA binding was significant, binding to non-CAGA
sequences accounted for the majority of pSmad2 association
within the ES cell genome suggesting that this was primarily
mediated by transcriptional co-partners. Indeed, when the top
consensus motifs in the center of all ChIP-seq peaks in each
signaling condition and in the combined dataset were studied
(Figure 5E), there was a strong enrichment for motifs belonging to
transcription partners such as E2f and Ap1 instead of Smad
binding CAGA boxes. To confirm the association of the putative
transcriptional cofactors and establish their identity, we expanded
the analysis to TRANSFAC co-motifs occurring within +/2 1k b
range of pSmad2 binding sites (Table S2). A large number of
known pSmad2 transcription partners such as Ap1, Sp1 and E2f
are indeed associated within the vicinity of pSmad2 peaks
regardless of the level of Nodal/Activin signaling. However, there
were additional co-motifs bound by transcription factors such as
Oct4, Stat3 and p53 that only appear prominently in Activin
treatments and Hes1, Lrf and Plzf appearing in SB. This is
supportive of an exchange of transcription partners in association
with pSmad2 that was governed by the level of Nodal/Activin
signaling which was likely to be responsible for the change in
specificity of pSmad2 transcriptional complexes for target gene
subsets and their level of expression. Furthermore, while pSmad2
does bind to its own CAGA sequence, transcriptional copartners
played a greater role both in binding affinity and specificity of
pSmad2 protein complexes for the ES cell genome.
Graded, Low Signaling Dominant, High Signaling
Dominant, and Multimodal Models of Binding Occur for
Phospho-Smad2 Target Genes
To investigate the different models of pSmad2 binding during
differential Nodal/Activin signaling, we examined the ChIP-Seq
profiles including those of the transcriptionally regulated micro-
array targets and identified at least 4 types of pSmad2 binding.
The first model is that of ‘‘graded’’ target genes that follow closely
the changes in Nodal/Activin signaling with increased binding and
transcription during high signaling, have moderate response in
endogenous baseline signaling and showed a loss of binding with
Nodal/Activin Signaling in ES Cell Fate Decisions
PLoS Genetics | www.plosgenetics.org 8 June 2011 | Volume 7 | Issue 6 | e1002130Figure 4. Phospho-Smad2 Binding to the Global ES Cell Genome Changes Dynamically in a Dose-Dependent Manner. (A) Proportional
Venn diagram of overlapping and treatment specific pSmad2 binding peaks identified by ChIP-Seq from same passage ES cells cultured for 18 hours
in Activin (ACT), DMSO control or SB in KSR media. Overlaps were defined using genomic coordinates of the start and end of peak positions identified
with the MACS program using the same parameters for each treatment. Total numbers of peaks are stated for each condition and percentage of
peaks in each Venn diagram segment is indicated in parentheses. (B) Graph showing frequency of pSmad2 peaks with respect to distribution in the
indicated genomic locations including the transcriptional start sites (TSS) and transcriptional termination sites (TTS) relative to mouse RefSeq genes.
Frequency is expressed as percentage of all pSmad2 binding peaks in conditions of high (Activin), medium (DMSO) and low (SB) signaling. (C) High
resolution view of pSmad2 binding frequency within +/22 kb of the TSS of target genes. Genomic distance is expressed in base pairs (bp) upstream
(negative) and downstream (positive) of the TSS while frequency is shown as percentage of pSmad2 binding peaks binned in 50 bp intervals out of
the total number of peaks for each treatment.
doi:10.1371/journal.pgen.1002130.g004
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PLoS Genetics | www.plosgenetics.org 9 June 2011 | Volume 7 | Issue 6 | e1002130Figure 5. Target Gene Expression Increases with Phospho-Smad2 Binding, Which Demonstrates Dose-Dependent Affinity for
Specific DNA Motifs. (A) Plot of relationship between pSmad2 binding affinity and expression levels of associated target genes in the Activin,
DMSO and SB conditions. Horizontal axis shows ,8000 RefSeq microarray targets ranked based on normalized log2 expression with a cutoff of 5.5 to
exclude non-expressing genes and non-functional probes. The largest pSmad2 ChIP-Seq peaks occurring within +/-50 kb of the RefSeq genes were
identified for each condition, normalized to average DMSO enrichments and subjected to a 500 gene moving average calculation on the vertical axis.
(B) Plot showing frequency distribution of basic CAGA Smad-binding DNA element (SBE) sequence in 100 base pair (bp) intervals up- and
downstream of ChIP-Seq peak positions. Horizontal axis shows distance in bp from the center (broken red line) of ChIP-Seq peaks and vertical axis
shows frequency of CAGA motifs in each interval. The frequency of CAGA sequences in 10,000 random mouse genome locations was computed as a
control for comparison (black line). (C) Plot of frequency distribution for the canonical Smad CAGAC sequence in intervals around ChIP-Seq peak
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of pSmad2 binding comprises 23.87% of high confidence ChIP-
Seq peaks corresponding to 16.28% of target genes associated
within +/250 kb of these peaks (Figure S4). Radil a Rap GTPase
effector that plays a role in the migration of neural crest
progenitors [52] exemplified such pSmad2 binding and transcrip-
tional regulation (Figure 3A, Figure 6A, and Table S1) in the first
intron with normalized relative enrichments of 107 tags in Activin
compared to 51 in the DMSO control and complete loss of
binding indistinguishable from background sequencing levels in
SB. The known target gene Pitx2 showed reproducible results with
the ChIP data obtained by real-time PCR (Figure S1A) both in
terms of the binding location in the intronic enhancer as well as
the level of pSmad2 enrichments under graded Nodal/Activin
signaling. There were normalized enrichments of up to 201 tags in
Activin, 156 in DMSO control and again complete loss of binding
in SB (Figure S3A). Interestingly, Pitx2 had 2 graded binding sites,
one of which is in the known intronic region and a novel site in the
39 region. The graded binding in the Pitx2 locus also correlates
with transcriptional consequences showing strong induction/
inhibition of Pitx2 mRNA levels from 0 to 24 hours (Figure 1A).
The two inducers of the mesendoderm cell fate Mixl [53] and
Nodal [54] also show evidence of graded pSmad2 binding within
50 kb of the genes (Figure S5A and S5B) suggesting that they may
be directly regulated by Nodal/Activin signaling for this purpose.
The binding location in the first intron of Nodal also corresponds to
the intronic enhancer previously described to be important for left
side expression in the early embryo via the Nodal/Activin
signaling autoregulatory loop [55,56] confirming that Nodal is
itself a direct target.
It was also unclear if pSmad2 binding and regulation of target
genes only exists in a 1-to-1 relationship or if the same binding sites
were capable of regulating multiple targets in the genomic vicinity.
While Lefty2 was a known direct target with pSmad2 binding in its
promoter region (Figure S1B), for the first time, to our knowledge,
we characterized an important pSmad2 transcriptional hotspot in
the entire 100 kb Lefty1/2 locus where all the genes within this
region were co-regulated by pSmad2 binding suggesting a
coordinated mode of transcriptional regulation (Figure S3B). This
was further confirmed in the microarray analysis (Figure 3A)
demonstrating that Lefty1/2, Pycr2 and Tmem63a display the same
pattern of gene expression following a graded response to Nodal/
Activin signaling. This was consistent with the real-time PCR
quantification of the pSmad2 pulldown of the Lefty2 promoter
(Figure S1B) that corresponds to the most upstream pSmad2
binding site in the Lefty1/2 hotspot as did a time course profiling of
Lefty2 expression from 0 to 24 hours (Figure 1B).
In the second model of pSmad2 binding, we describe ‘‘low
signaling dominant’’ conditions that permit pSmad2 binding but
less so under other signaling levels. The Id1/2/3 (Figure 6B,
Figure S6, and Table S1) family of transcriptional repressors shows
pSmad2 binding to these genes only in the SB treatments and not
in Activin or the DMSO control. Statistically, 32.73% of pSmad2
binding sites display this mode of behavior associated with 23.44%
of target genes (Figure S4). In contrast, the third model showed the
opposite ‘‘high signaling dominant’’ mode of binding such as in the
case of 220011C2Rik (Figure 6C and Table S1) where pSmad2
only binds strongly in the Activin condition but to a lesser degree
in DMSO or SB also resulting in transcriptional consequences
(Figure 3A and Figure S4). Another known component of the
mesendodermal cell fate Fgf8 [57] also shows strong pSmad2
binding in the promoter region specifically during high signaling
(Figure S5C). Intriguingly, findings in the chick embryo show that
Fgf8 also plays important roles in left-right asymmetry where it can
be induced by Activin [58] in agreement with our results.
In the fourth model which accounts for the regulation of the
largest proportion (33.69%) of target genes associated with
pSmad2 ChIP-Seq peaks (Figure S4B), the same target gene
may be regulated by ‘‘multimodal pSmad2 binding’’ events. Copz2
has two pSmad2 association sites in the intron and promoter
region (Figure 6D). The promoter site only binds pSmad2 in the
SB condition while the intronic enhancer shows a graded response
to the signaling level. In the case of the known target gene Smad7,
we have shown that the pSmad2 binding peak in the promoter
region is invariant in all 3 signaling conditions (Figure S1C) which
could not explain how Smad7 was differentially expressed during
graded Nodal/Activin signaling (Figure 1C). In confirmation with
these results, the ChIP-Seq data showed the same pSmad2
association on the Smad7 proximal region with no change in
binding under all 3 signaling conditions. Surprisingly, we
discovered a previously undescribed pSmad2 regulatory element
in the distal Smad7 promoter region that binds pSmad2 in a graded
manner (Figure S3C) and could account for why Smad7 was
responsive to different Nodal/Activin signaling levels. Hence
pSmad2 binding in the Smad7 proximal region may not be the
dominant regulatory region for Nodal/Activin signaling but may
depend instead on the dynamically changing pSmad2 distal
promoter element for Smad7 regulation. Indeed the proximal
promoter element may be more of a Smad3 regulated region
instead of Smad2 as previously described [38].
In conclusion we demonstrate that pSmad2 dependent binding
and transcription during graded Nodal/Activin signaling occurs in
the ES cell genome in a graded, low or high signaling dominant,
many-to-one or one-to-many multimodal manner in relation to
the target genes that they regulate.
Nodal/Activin Signaling Titrates the Level of Oct4 in ES
Cells, Which Is a Direct Target of Phospho-Smad2 Binding
in the Promoter Region
The mesendodermal and trophectodermal cell fate decisions
brought about by graded Nodal/Activin signaling strikingly
resemble the ES cell response to a less than 2-fold up- or
downregulation of the Oct4 master regulator of stemness in driving
differentiation towards similar cell fates [59]. Furthermore, an
important mechanism for trophectoderm differentiation depends
on the Oct4 repression of Cdx2 expression and the induction of this
lineage is thought to be indicative of loss of stemness [60]. We
therefore hypothesized that Oct4 may be a key downstream target
under Nodal/Activin control during the specification of divergent
cell fate decisions and investigated how the pathway may be
governing Oct4.
positions using the same control calculations as in (B). Insert shows the logo of the Smad binding motif (TRANSFAC PWM SMAD_Q6_01) containing
the CAGAC sequence. (D) Graph showing the sequence and frequency of the top 6-mer motifs in Activin, DMSO and SB. The motifs were defined by
the Weeder program using sequences that occur only in the center of ChIP-Seq peaks. The frequency is expressed as fraction of +/–25 bp sequences
spanning ChIP-Seq peaks containing the indicated motifs. CAGA containing 6-mers are highlighted in red. (E) 8-mer motifs defined by Weeder
program in top 1000 ChIP-Seq peaks ranked by enrichments in +/250 bp intervals for Activin, DMSO, SB and combined conditions correspondingly.
Transcription factors binding to sequences similar to these motifs identified by the STAMP program using TRANSFAC PWM are indicated with
corresponding p-values.
doi:10.1371/journal.pgen.1002130.g005
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PLoS Genetics | www.plosgenetics.org 11 June 2011 | Volume 7 | Issue 6 | e1002130Figure 6. Graded, Low Signaling Dominant, High Signaling Dominant, and Multimodal Modes of Phospho-Smad2 Target Gene
Binding. UCSC Genome Browser representation of pSmad2 enrichment peaks under Activin (red), DMSO control (blue) and SB (green) signaling
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binding events from ChIP-Seq profiling (Figure 7A). During
graded Nodal/Activin signaling in chemically defined conditions
however, only a pSmad2 peak in the promoter region of Oct4
showed a similarly graded response suggesting that this was the
functional Nodal/Activin signaling response element. We exam-
ined the transcript levels of endogenous Oct4 expression (Figure 7D)
upon inhibition of Nodal/Activin signaling with SB in serum
containing media and found that it was also significantly
downregulated within 24 hours. In agreement with the transcript
data, Oct4 protein levels were similarly downregulated in SB
treated ES cells (7E). Analysis of the 503 bp promoter region
encompassing the beginning and end of the pSmad2 binding peak
showed that it contained eight CAGA sites or their inversion
(Figure 7B). To determine if this regulatory sequence was indeed a
Nodal/Activin response element of the Oct4 promoter, we cloned
this into luciferase reporter constructs and transfected ES cells
subjected to the 3 signaling conditions with Activin, DMSO and
SB (Figure 7C) in serum containing media. The reporter activity of
the wild type Oct4 promoter construct was .100X higher than
that of the empty reporter construct in the DMSO control
signaling condition suggesting that the 503 bp sequence had
strongly driven Oct4 promoter activity in ES cells. Crucially, the
Oct4 promoter reporter displayed a specific graded response to
Nodal/Activin signaling while the control empty reporter did not.
To confirm that the Oct4 response to graded Nodal/Activin
signaling was functionally driven by pSmad2 binding, we
determined the exact SBE responsible for Oct4 inducibility
(Figure 7C). Mutagenesis experiments on the Oct4 promoter
region in luciferase assays revealed that the strong CAGAC
consensus SBE site in the middle of the 503 bp fragment was
indispensable for graded Oct4 promoter activity. Loss of this site
completely abolished the promoter response to both high and low
Nodal/Activin signaling. Further point mutations of two minimal
CAGA SBEs flanking the CAGAC site led to no further significant
effects on the Oct4 promoter.
We therefore conclude that Oct4 is a direct target of pSmad2
binding and Nodal/Activin signaling regulates both its promoter
activity and endogenous expression. The 503 bp Oct4 promoter
response element with the essential CAGAC SBE was sufficient
and independent of all other pSmad2 binding events in the Oct4
locus or other DNA regulatory elements in cis that may be
mediated by Nodal/Activin signaling. The regulation of Oct4 is
well known for its importance in cell fate decisions and its
downregulation during loss of Nodal/Activin signaling is signifi-
cant not only as an impetus for trophectoderm differentiation but
also reconciles the alternative role of Nodal/Activin signaling in
maintaining self-renewal and pluripotency.
Discussion
The molecular basis of extracellular signaling instructions
governing differential cell fate decisions in the Nodal/Activin
pathway has been postulated but not shown conclusively.
Primarily, the transcriptional events occurring at the interface
between pSmad2 signal transduction from the activated cell
surface receptors to manipulation of the global stem cell
transcriptome driving specific lineage programs have not been
well characterised. This study provides an important insight into
how quantitative signaling is translated into qualitative cell fate
decisions by showing for the first time, to our knowledge, that the
same transcription factor pSmad2 is able to bind and transcrip-
tionally regulate different subsets of target genes in a dose-
dependent manner.
The specification of cell fate decisions is governed by 2 distinct
events. The first requires an exit from self-renewal and
maintenance of stemness programs by direct control of pSmad2
over key pluripotency factors. Previous studies have revealed that
Nanog is a direct target of Smad2/3 transcription in human ES cells
[61]. Here we show an additional level of control over the stem cell
program by direct transcriptional regulation of the Oct4 master
pluripotency gene by pSmad2. The second event requires an entry
into a specific differentiation program that is in turn brought about
by direct and indirect pSmad2 regulation of differentiation genes
such as Gata3, Tcfap2c and Igf2 that are known to be important
factors for trophectoderm cell fates. This cell fate decision is
further reinforced by loss of Oct4 with inhibition of Smad2
phosphorylation as the former is known to be a potent repressor of
the trophectoderm gene Cdx2 in the blastocyst [60]. The pSmad2
binding target genes driving mesendodermal differentiation
include Mixl, Fgf8 and Nodal itself, while other genes such as
Chst15 expressed in definitive endoderm and Fgf15 for cardiac
mesoderm have also been identified as strong Nodal/Activin
transcriptional targets. It is likely that over the course of long-term
differentiation for 6 days, additional target genes may be recruited
for the specification of both lineage decisions that may not be
apparent at the 18 hours time point in this study which may be too
early for endpoint differentiation. Indeed, strong regulation of Mixl
and Fgf8 and to a lesser extent Nodal could be detected at 3 and 6
days (Figure 2B and data not shown) of treatment in correlation
with the level of Nodal/Activin signaling.
Consistent with the role of Nodal/Activin as morphogens, we
found that many components of the pathway were themselves
feedback targets that were directly regulated by pSmad2 binding
in ChIP-Seq and/or differentially expressed in our microarray
analysis. These include the negative feedback inhibitors such as
Lefty1/2 and Smad7 which are already known targets of Nodal/
Activin signaling. In this study, graded pSmad2 binding could be
detected in the intronic region of Tmepai (Figure S6) which
sequesters Smad2/3/4 from receptor kinase activity [62].
Similarly, SnoN [63] and Ski [64] also present graded intronic
binding of pSmad2 (Figure S6) and both function as transcrip-
tional repressors of Smad2/3/4. There were also positive feedback
components such as Nodal, its cofactor Cripto and FoxH1 the
transcriptional copartner of Smad2 (Figure 8 and Figure S6) that
show graded binding in the intron and promoter regions. The
preponderance of the negative components in the autoregulatory
loop of Nodal/Activin signaling is significant, as it suggests that the
conditions in ES cells. Genomic locations of signaling regulated peaks correspond to (A) graded binding to intron of Radil in all 3 conditions, (B)
discrete binding to promoter and exon of Id1 specific to SB treatment, (C) binding to the 39 region of 2210011C2Rik only in the Activin condition and
(D) multimodal recruitment of pSmad2 in ChIP-Seq peaks marked with (*) where it is SB specific in the promoter region of Copz2 and graded in
correlation with signaling in the intronic region. All target genes were identified to be differentially expressed under the 3 signaling conditions in the
microarray analysis of Figure 3A. Top panels show raw sequencing tag enrichments in Activin/DMSO/SB on the vertical axis. Bottom panels show
ChIP-Seq peak positions and intensities defined by the MACS program based on normalization to the respective input DNA sequencing controls for
each condition. Horizontal scale shows genomic coordinates on the indicated chromosomes and scale bar denotes genomic distance. Structure of
the indicated target genes is represented by thick solid lines for exons, thin solid lines for UTRs and continuous arrows running from 59 to 39 for
introns.
doi:10.1371/journal.pgen.1002130.g006
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PLoS Genetics | www.plosgenetics.org 13 June 2011 | Volume 7 | Issue 6 | e1002130Figure 7. Oct4 Is a Direct Target of Nodal/Activin Signaling via Graded Phospho-Smad2 Recruitment to the Promoter. UCSC Genome
Browser plot of the Oct4 genetic locus showing pSmad2 ChIP-Seq enrichment on the vertical scale in ES cells subjected to Activin (red), DMSO control
(blue) and SB (green) treatments with genomic distance in bp on the horizontal scale. Colored bars show ChIP-Seq peak positions and normalized
enrichments for each treatment. (B) 503 bp sequence of the Oct4 promoter region marked with asterisk (*) in (A). Sequences in yellow show canonical
CAGA SBEs or their inverted sequence TCTG while the strong CAGAC SBE is highlighted in blue. Sequences in red boxes denote where mutations
were made in the indicated luciferase constructs. (C) Firefly luciferase assays of the 503 bp sequence cloned into the pGL4.23 reporter construct
(pGL4.23 Oct4) or mutated in the strong CAGAC SBE (pGL4.23 m4 Oct4) or mutated in CAGAC and the two flanking CAGA sites (pGL4.23 m345 Oct4).
The constructs were transfected into ES cells treated with Activin (dark gray bars), DMSO control (light gray) and SB (white). Discontinuous vertical
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negative feedback and less so by positive feedback loops mediated
by Nodal, Cripto and FoxH1.
One of the intriguing findings is that extracellular signaling
gradients were translated into a gradient of Smad2 phosphoryla-
tion that we have now shown to be able to recruit different target
genes in a dose-dependent manner. This was possibly achieved by
an exchange of transcriptional copartners that permits the shifting
of the pSmad2 transcriptional complex to different target gene
subsets as suggested by the differential recruitment of non-CAGA
motifs and comotifs under each signaling condition. The fact that
pSmad2 contains only CAGA sequence binding domains and not
transcription activation domains suggest that it is further
dependent upon copartners for transcription, binding affinity
and specificity. In some cases graded pSmad2 transcription
complex binding drives graded target gene response that follows
signaling strength with high fidelity. In other cases, the target
genes are only regulated and responsive at defined signaling
thresholds (Figure 8). The consequence is that a relatively modest
stimulation with Activin leading to a physiological 2-fold increase
in Smad2 phosphorylation eventually drives mesendodermal
differentiation while the reciprocal SB inhibition resulting in a 2-
fold decrease of pSmad2 is able to promote trophectoderm cell
fates. During this process, the master regulator of pluripotency
Oct4 is itself titrated by the same Nodal/Activin signaling gradients
in the ES cells undergoing differentiation. Hence the same
pathway is able to tilt the balance in favor of maintenance of
pluripotency or mediate an exit from self-renewal and entry into a
specific lineage program. In conclusion, this study for the first
time, to our knowledge, reconciles the multiple divergent roles of
Nodal/Activin signaling in both pluripotency and differentiation
with pSmad2 playing a central role in the cell fate decision making
process.
Materials and Methods
Cell Culture
E14 TG2A mouse embryonic stem cells (ATCC) were
propagated in FBS media consisting of 20% ES cell-qualified
FBS in DMEM supplemented with 100 mM non-essential amino
acids, 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM
GlutaMAX-I (Invitrogen), 55 mM b-mercaptoethanol (Sigma)
and 1X homemade Leukemia inhibitory factor (LIF). For the
establishment of Nodal/Activin signaling gradients in chemically
defined conditions, KSR media containing 20% Knockout Serum
Replacement (KSR, Invitrogen) in place of FBS with all other
components of ES media excluding LIF were used. For acute (0 to
48 hours) signaling conditions, 25000 ES cells/cm
2 were plated for
18 hours in FBS media followed by adaptation of the cells to
chemically defined conditions with 10 mM SB-431542 (Tocris) in
KSR media for 6 hours as previously described [41]. High
signaling was induced by treatment with KSR media containing
25 ng/ml Activin (R&D Systems) or low signaling with 10 mMS B
and maintenance of endogenous signaling with control KSR
media or 1/5000 dilution of DMSO vehicle as indicated. For long-
term differentiation, 2000 ES cells/cm
2 were plated and 18 hours
later directly treated with Activin, DMSO and SB in FBS media
without LIF or KSR media for 6 days with media change
everyday. The DMSO vehicle used to dissolve SB can induce
differentiation and loss of pluripotency in ES cells [65,66]. In the
microarray analysis of the 3 signaling conditions, the effect of
DMSO on differential gene expression was determined by
comparing against the unsupplemented KSR media control
(Figure 3A). The SB inhibitor was used at a high stock
concentration of 50 mM permitting 5000X dilution of DMSO
in ES cell cultures which was well below the limit required for
differentiation. The cultures and treatments were carried out for
the microarray study in 4 biological replicates consisting of ES cells
at 4 different passages from P20 to P24 to identify and eliminate
any cell culture variation effects from analysis.
Western Blotting
ES cells were lysed in RIPA buffer (150 mM NaCl, 1% NP-
40, 0.5% Sodium Deoxycholate, 0.1% SDS, 50 mM Tris pH
8.0) for protein extracts. SDS-PAGE was performed on 10%
polyacrylamide gels and transferred on Immun-Blot PVDF
membranes (Bio-rad Laboratories) followed by probing with
1:1000 dilutions of rabbit anti-Smad2 (pSer
465/467, Calbiochem),
rabbit anti-Smad2 (Invitrogen), mouse anti-Pcna (Santa Cruz
Biotechnology) and goat anti-Oct4 (Santa Cruz Biotechnology).
Secondary antibodies used were 1:1000 donkey anti-rabbit IgG-
HRP (GE Healthcare), 1:1000 goat anti-mouse IgG-HRP and
1:2500 donkey anti-goat IgG-HRP (Santa Cruz Biotechnology).
Densitometry measurements of protein bands on western blots
were acquired using Photoshop CS3 (Adobe Systems Incorpo-
rated).
PCR Quantitation of Gene Expression and ChIP DNA
Enrichments
For gene expression, total RNA was extracted from cells using
the RNeasy Mini kit (Qiagen) as per manufacturer instructions.
This was reverse transcribed into cDNA using the High Capacity
RNA-to-cDNA Master Mix (Applied Biosystems). Quantitative
real-time PCR was performed on the 7900HT Fast Real-Time
PCR System (Applied Biosystems) or the Biomark System
(Fluidigm Corporation) on cDNA or ChIP DNA according to
manufacturer instructions. For RT-PCR, products amplified for
25 to 33 cycles were resolved on a 2.5% agarose gel. Primer
sequences for both ChIP-qPCR and gene/marker expression can
be found in Table S3.
Microarray Analysis
Total RNA was reverse transcribed into cDNA and in vitro
transcribed into biotin-labeled cRNA using the Illumina Total-
Prep RNA Amplification kit (Ambion). This was hybridized on
MouseRef-8 v2.0 Expression BeadChips (Illumina). Raw intensity
values were subjected to background subtraction on the Bead-
Studio Data Analysis Software (Illumina) and normalized using the
cross-correlation method [67]. Differential gene expression was
identified based on a fold change cutoff of .1.5 compared to the
DMSO control. The microarray data was deposited in NCBI
GEO with accession number GSE23239.
scale shows relative Firefly luciferase levels normalized to the co-transfection pGL4.75 Renilla luciferase control. Error bars provide s.e.m. for n=8
replicates. (D) Real-time PCR quantitation of endogenous Oct4 expression in ES cells treated for 0 to 48 hours in SB (gray bars) compared to DMSO
(white bars) after normalizing to the Ywhaz housekeeping control. Vertical axis shows fold change over the 0 h control in each treatment. Error bars
show s.e.m. for n=8 replicates. (E) Western blot of endogenous Oct4 protein levels in ES cells after treatment with SB or DMSO control in a 0 to 24
hour time course. Pcna was used as a loading control in both conditions. Densitometry plot shows Oct4 protein quantitation after normalizing to the
respective Pcna loading control with the relative level at 0 hours for each treatment at 100%.
doi:10.1371/journal.pgen.1002130.g007
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PLoS Genetics | www.plosgenetics.org 15 June 2011 | Volume 7 | Issue 6 | e1002130Figure 8. Model of the Mechanism of ES Cell Fate Decisions Directed by Graded Nodal/Activin Signaling. Schema of the components
and signal transduction of the Nodal/Activin pathway starting with different concentrations of ligands external to the ES cell lipid bilayer membrane
and terminating with the pSmad2 transcriptional complex regulating Oct4 and different subsets of target genes in the nucleus. Red arrows show the
signal transduction circuit, black arrows show transcription and translation of pSmad2 target genes while green inhibitory lines indicate negative
feedback. Protein names in red are targets identified in the microarray analysis and/or pSmad2 ChIP-Seq. Color gradients from red to green denote
components exhibiting a dose-dependent response from high (+) to low (–) activity. Plots represent the graded, high and low signaling dominant
models of pSmad2 binding during differential signaling with the vertical axis showing the level of binding against the horizontal axis with increasing
signaling levels from left to right. Different cell fate decisions and the events triggering them are indicated by lines and arrows in red to green color
gradients.
doi:10.1371/journal.pgen.1002130.g008
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Chromatin Immunoprecipitation (ChIP) using a certified ChIP-
grade rabbit polyclonal anti-Smad2 (phospho S465+S467) anti-
body (ab16509, Abcam) was carried out in ES cells under
chemically defined high, medium or low Nodal/Activin signaling
conditions according to the Agilent Mammalian ChIP-on-chip
protocol v9.1 up to the ChIP DNA purification step. Adapter
ligation, library amplification and size selection in the 200–300 bp
range were performed according to the Illumina ChIP Sample
Prep protocol (#11257047, Rev. A). Massively parallel sequencing
was carried out for ChIP samples in all 3 signaling conditions with
their respective input DNA controls on the Genome Analyzer
(Illumina) up to a sequencing depth of at least 10610
6 tags pass
filter. The ChIP-Seq data was deposited in NCBI GEO with
accession number GSE23581. Details of the ChIP-Seq, motif and
statistical analysis can be found in the Text S1.
Luciferase Assays
The 503 bp fragment of the mouse Oct4 promoter region
corresponding to chr17:35640683–35641185 was cloned into the
pGL4.23[luc2/minP] Firefly luciferase reporter construct (Pro-
mega) to generate pGL4.23 Oct4. This construct was point mutated
by oligo cloning into unique StuI and NsiI sites to produce
pGL4.23 m4 Oct4 (CAGAC mutated to CATGC) and pGL4.23
m345 Oct4 (TCTGGGCAGACGGCAGA mutated to TATGGG-
CATGCGGCATA). The constructs were transfected into mouse
ES cells in an 80:1 ratio with the pGL4.75[hRluc/CMV] Renilla
luciferase co-transfection control (Promega) using Lipofectamine
2000 (Invitrogen). A control transfection was included with an
80:1 ratio of the empty pGL4.23 vector to pGL4.75 Renilla
control. Immediately after lipofections, the ES cells were
pretreated with FBS media without LIF and with 10 mM SB for
6 hours. Subsequently the cells were split into replicates and plated
in FBS media without LIF containing 25 ng/ml Activin, 1/5000
DMSO vehicle or 10 mM SB, which induces high, medium or low
Nodal/Activin signaling respectively for 8 hours. The cells were
washed once in PBS and lysed in 1XPassive Lysis Buffer and
luciferase assays were performed using the Dual-Luciferase
Reporter Assay System on the GloMax 96 Microplate Luminom-
eter with Dual Injectors (Promega).
Supporting Information
Figure S1 There Is Graded pSmad2 Binding to Pitx2 and Lefty2
but Not the Smad7 Proximal Promoter. Real-time PCR quantifi-
cation of pSmad2 ChIP enrichments using tiling primers across
the intronic enhancer in Pitx2 (A) and the promoter regions of
Lefty2 (B) and Smad7 (C). Y-axis shows fold enrichment over the
non-binding control region in the Sox2 locus after normalizing to
the input DNA for each condition while the x-axis represents
genomic distance in base pairs (bp) from the transcriptional start
site (TSS) of each gene. Upstream and downstream distances are
denoted as negative and positive coordinates respectively. Trends
show the level of pSmad2 ChIP enrichment for the indicated
genomic regions obtained from ES cells treated with Activin (red),
DMSO carrier control (blue) and SB (red) in chemically defined
KSR media. Horizontal bars show coverage of each PCR primer,
vertical error bars show s.e.m. for n=3 replicates.
(TIF)
Figure S2 Activin/SB Treatments of ES Cells Promote Exit
from Self-Renewal towards Mesendoderm and Trophectoderm
Differentiation. Immunofluorescence detection of the markers of
pluripotency and mesendoderm or trophectoderm differentiation
in ES cells treated for 6 days with Activin, DMSO control and SB.
Phase contrast bright field (BF) images are in the top panels
followed by Hoechst 33342 nuclear staining in blue. Alexa Fluor
546 staining for Lim1, Oct4 and Hand1 are in red for Activin,
DMSO and SB treated cells respectively. Alexa Fluor 488 staining
for Mixl, SSEA-1 and placental Cadherin (P-cad) are in green
while overlays of all fluorescent channels (Merge) are shown in the
bottom panels. Scale bar shows distance under a 20X objective
lens.
(TIF)
Figure S3 Pitx2, the Lefty1/2 Hotspot, and Smad7 Contain
Multiple pSmad2 Regulatory Sites in Their Genetic Loci. UCSC
Genome Browser representation of the genomic loci for Pitx2 (A)
on chromosome 3:128,894,461–128,931,307, Lefty1/2, Pycr2 and
Tmem63a (B) on chromosome 1:182,813,583–182,908,336 and
Smad7 (C) on chromosome 18:75,513,703–75,561,010. Genomic
coordinates are shown on the x-axis while raw pSmad2 ChIP-Seq
tag counts are presented on the y-axis in the top panel followed by
relative enrichments normalized to the respective input DNA
controls of Activin (red), DMSO (blue) and SB (green) treated ES
cells in the bottom panel. The RefSeq genetic structures of the
indicated genes and their isoforms if any are indicated below the
ChIP-Seq panels. Scale bar shows genomic distance in kilo base
pairs (kb) while pSmad2 enrichment peaks corresponding to the
real-time PCR results in Figure S1 are indicated with asterisks (*).
(TIF)
Figure S4 Phospho-Smad2 Binding to Majority of Sites and
Target Genes Varies by .1.25-Fold during Graded Signaling. Pie
charts showing patterns and statistics of pSmad2 binding to sites
and target genes that vary by at least 1.25-fold during Activin,
DMSO and SB treatments. Colored segments display the
indicated models of pSmad2 binding in the 3 signaling conditions.
Proportional segment sizes define the relative contribution of each
type of binding behavior for ChIP-Seq peaks (A) and target genes
within +/250 kb of the peaks (B) out of the total for each. Values
indicate the number of peaks (A) or genes (B) in each regulatory
model with percentages of the total in parentheses.
(TIF)
Figure S5 The Mesendodermal Genes Mixl, Nodal, and Fgf8 Are
Targets of Differential pSmad2 Binding. Binding profile of
pSmad2 ChIP-Seq enrichments on Mixl (A), Nodal (B) and Fgf8
(C) as visualized on the UCSC Genome Browser at the
coordinates chr1:182,571,609–182,632,748, chr10:60,873,730–
60,895,009 and chr19–45:805,804–45,822,014 respectively.
Changes in the level of pSmad2 ChIP-Seq peak enrichments
(raw peaks top panel, normalized peaks bottom panel) are
indicated for Activin (red), DMSO (blue) and SB (green) treated
ES cells on the y-axis. X-axis shows genomic location and genetic
features of the indicated genes are below the Genome Browser
panels. PSmad2 binding peaks showing significant differential
binding with Nodal/Activin signaling are marked with asterisks (*).
Scale bar shows genomic distance in kilo base pairs (kb).
(TIF)
Figure S6 Validation of 15 Genes as Direct Targets of Nodal/
Activin Signaling via Differential Phospho-Smad2 Binding. Real-
time PCR validation of pSmad2 ChIP-Seq enrichment on original
unamplified ChIP DNA from ES cells treated with Activin (ACT),
DMSO and SB in KSR media for 18 hours. Indicated genes were
selected based on transcriptional regulation under the same
conditions in the microarray analysis of Figure 3A and real-time
PCR gene expression detection in Figure 7D. Vertical scale shows
fold-enrichment over the non-binding control region in the Pfkm
locus on chromosome 15:97,934,552–97,934,626 after normaliza-
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enriched regions detected by the PCR primers are indicated in the
genomic coordinates above each graph. Error bars show s.e.m. for
n=12 replicates.
(TIF)
Table S1 64.2% of Microarray Targets Differentially Expressed
by .1.5-fold are also Targets of Differential Phospho-Smad2
Binding. Table showing 104 out of the 162 microarray target genes
from Figure 3A where expression is induced and/or repressed by
.1.5-fold during stimulation or inhibition of Nodal/Activin
signaling in ES cells. These targets also exhibit pSmad2 binding
at +/250 kb from the 59/39UTRs and within the genes themselves.
Only ChIP-Seq peaks that satisfy a size cutoff of .12 sequencing
tags in at least 1 condition are considered significantly above
background sequencing levels and counted for each gene during
Activin (ACT), DMSO vehicle control and SB inhibitor treatments.
GeneIDsofthe targetgenes,theirchromosomallocations(Chr)and
their orientation on the sense (+)/antisense (2) strands are as
indicated. Gene names highlighted in yellow are for Activin/SB co-
regulated targets, red for Activin specific targets and green for SB
responsive genes only. The number of sequencing tags within the
largest ChIP-Seq peaks for each gene and under each condition are
as shown. For genes that contain multiple pSmad2 binding sites, the
largest peaks counted may not occur at the same genomic location.
Changes in the level of overall pSmad2 binding during Activin
treatment compared to SB (ACT vs SB), Activin compared to
DMSO control (ACT vs DMSO) and SB compared to DMSO (SB
vs DMSO) are shown as (+) for increased binding and (–) for
decreased binding by .1.5-fold. The overall level of pSmad2
binding for each gene is calculated as the sum of all peak heights
(enrichment counts)proximal to the gene and under eachcondition.
A value of 0 denotes no significant change in binding at a 1.5-fold
cutoff and NA indicates no detectable peaks for statistical analysis.
(DOC)
Table S2 There Are Dynamic Changes in Phospho-Smad2
Binding Motifs During Graded Nodal/Activin Signaling. Moti-
fEnrich program identification of co-motifs enriched within
#5000 bp of pSmad2 binding peaks. Co-motifs are ranked based
on frequency of occurrence from highest to lowest. Matching of
co-motifs with associated transcription factors was performed
using the TRANSFAC PWM database with p-value thresholds of
1e-05. Transcription factor names in black are present across all 3
signaling conditions with Activin, DMSO and SB treatments.
Activin enriched transcription partners binding on the co-motifs in
proximity to pSmad2 sites are highlighted in red, DMSO enriched
factors in blue and SB in green. The intervals of significant
enrichment for each co-motif are indicated in base pairs (bp).
(DOC)
Table S3 Primers Used for Quantification of ChIP DNA and
Marker/Gene Expression Levels by Real-Time PCR. List of
forward/reverse primer pairs used in SYBR Green real-time PCR
reactions for the quantification of ChIP-DNA (ChIP-qPCR) and
Marker/Gene expression. For tiling ChIP-qPCR analysis of
pSmad2 binding on Pitx2, Lefty2 and Smad7, primers for each
gene are numbered sequentially according to the 59–39 order of
their respective amplified regions shown in Figure S1.
(DOC)
Text S1 Supporting Experimental Procedures and Supporting
References. Description of methods used for motif identification
and statistical analysis of ChIP-Seq data and immunostaining of
the protein markers of differentiation in cells with the associated
supplementary references.
(DOC)
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